PRCT Stock Recent News
PRCT LATEST HEADLINES
PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.39 per share a year ago.
PROCEPT BioRobotics Corporation (PRCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REDWOOD CITY, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the first quarter of 2023 before market open on Thursday, April 27, 2023. The Company's management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time.
REDWOOD CITY, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming Virtual Key Bank Life Sciences & MedTech Investor Forum. Management is scheduled to present on Tuesday, March 21 at 12:45 p.m. Eastern Time. A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the company's website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.
PROCEPT BioRobotics Corporation (PRCT) delivered earnings and revenue surprises of -5.66% and 0.33%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
REDWOOD CITY, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 43rd Annual Cowen Health Care Conference in Boston. Management is scheduled to present on Tuesday, March 7 at 12:50 p.m. Eastern Time. A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the company's website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.
PROCEPT BioRobotics endured a volatile start to the new year, eventually breaking above its longer-term resistance line. Market generated data is still supportive for a re-rating heading into its FY22 earnings.
REDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference. Management is scheduled to present on Tuesday, January 10 at 9:45 a.m. Pacific Time. A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the company's website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.
PROCEPT BioRobotics Corporation reported 135% YoY Q3 revenue growth to $20.3mm. Growth was underscored by robotic system sales and utilization from current placements.
PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q3 2022 Earnings Call Conference Call November 3, 2022 4:30 PM ET Company Participants Matt Bacso – Vice President-Investor Relations Reza Zadno – Chief Executive Officer Kevin Waters – Senior Vice President and Chief Financial Office Conference Call Participants Craig Bijou – BofA Securities Nathan Treybeck – Wells Fargo Richard Newitter – Truist Securities Ryan Zimmerman – BTIG Neil Chatterji – B. Riley Matthew Mishan – KeyBanc Philip Coover – Goldman Sachs Joshua Jennings – Cowen Operator Good day.